Tofajak (Tofacitinib) 5 mg
Tofajak 5 mg (Tofacitinib) is an oral Janus kinase (JAK) inhibitor used for autoimmune conditions.
Manufacturer: Cipla (India). Tofajak is a generic equivalent of the brand-name drug Xeljanz.
Mechanism of Action ("Signal Blocker"):
Tofacitinib works inside the cell by blocking the activity of JAK enzymes. These enzymes play a key role in signaling the cytokine pathways that cause inflammation. By inhibiting them, the drug effectively "mutes" the immune system's attack on the body's joints or digestive tract.
✅ Key Benefit: Reduces joint pain, swelling, and structural damage in arthritis; induces remission in ulcerative colitis.
Indicated for adult patients with moderate to severe:
- 🦴 Rheumatoid Arthritis (RA): For patients who have had an inadequate response to Methotrexate.
- 🖐️ Psoriatic Arthritis (PsA).
- 🚽 Ulcerative Colitis (UC).
- Ankylosing Spondylitis.
Packaging: Bottle of 60 Tablets (5 mg each).
⚠️ ADMINISTRATION PROTOCOL:
- 💊 Standard Dosage: 5 mg taken orally twice daily (BID).
- 🍽️ Food: May be taken with or without food. Swallow whole.
- Adjustment: Dosage may be reduced to once daily in patients with moderate renal/hepatic impairment or those taking strong CYP3A4 inhibitors.
- Active serious infections (including localized infections). Screening for Tuberculosis (TB) is mandatory prior to administration.
- Severe hepatic impairment.
- Pregnancy and breastfeeding.
- History of thrombosis (blood clots).
Potential side effects to monitor:
- 🦠 Infections: Upper respiratory tract infections (common cold), nasopharyngitis.
- 🔥 Herpes Zoster: Increased risk of shingles.
- 🩸 Thrombosis: Use with caution due to risk of pulmonary embolism (PE) and deep vein thrombosis (DVT).
- Increased cholesterol levels.
Similar products
What Customers Say
No reviews yet
Your review can be the first!